2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
10:30 a.m. - 12:00 p.m.
MCCNO - La Nouvelle C
Efficacy of T cell engagers and anti-CD38 therpies in real world studies
Access, Representation, Population Health, Treatment Considerations, Combination Therapy, Therapy Sequence, Biological Therapies, Bispecific Antibody Therapy, Immunotherapy, Non-Biological Therapies, Chemotherapy, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Research, Clinical Research, Epidemiology, Real-World Evidence, Study Population, Human, Adult
PAPER

841 Efficacy and safety of BCMA CAR-T therapy versus BCMA bispecific antibodies in later-line BCMA-Naïve relapsed/refractory multiple myeloma

Saurabh Zanwar, MBBS, MD, Alicia Richards, PHD, MS2, Surbhi Sidana, MD3, Doris K. Hansen, MD4, Lauren C Peres, PhD, MPH5, Andrew Jay Portuguese, MD6, Doug W. Sborov, MD, MS7, Noa Biran, MD8, Bruno Almeida Costa, MD9, Christopher J. Ferreri, MD10, Jack Khouri, MD11, James A Davis, PharmD, BCOP12, Murali Janakiram, MBBS13, Leyla Shune, MD14, Aimaz Afrough, MD15, Sneha Purvey, MD16, Marcus Geer, MD17, Ran Reshef, MD18, Megan M Herr, PhD19, Mikhaila Rice, PharmD20, Vanna Hovanky21, Andre De Menezes Silva Corraes, MD22, Omar Alexis Castaneda Puglianini, MD23, Kenneth H. Shain, MD, PhD24, Masooma Rana25, Raffaella Cassano Cassano, MD26, Ciara Louise L Freeman, MD, PhD27, Melissa Alsina, MD28, Nilesh Kalariya, APRN, PhD29, David Berrios, M.D.30, Jing Christine Ye, M.D., MSc31, Lindsay Fogel, MD32, Evguenia Bhurtel, MD33, Saurabh Chhabra, MD, MBBS34, Ricardo Daniel Parrondo, MD35, Tiffany Richards, PhD, NP36, Anthony Dominick37, Christopher Cahoon, PharmD38, Shebli Atrash, MD39, Lekha Mikkilineni, MD, MA40, Kelley Julian, PharmD, BCOP41, Danai Dima, MD42, Rahul Banerjee, MD43, Shahzad Raza, MD44, Faiz Anwer, MD45, Cindy Varga, MD,BSc46, Larry D Anderson Jr, MD, PhD47, Yi Lin Jr, MD, PhD48, Krina Patel Jr, MD, MSc49, Ariel Grajales-Cruz, MD50
1 Mayo Clinic, Rochester, Minnesota, United States
2 H. Lee Moffitt Cancer Center, Tampa, Florida, United States
3 Stanford University School of Medicine, Stanford, California, United States
4 H. Lee Moffitt Cancer Center, Tampa, Florida, United States
5 H. Lee Moffitt Cancer Center, Tampa, Florida, United States
6 Fred Hutchinson Cancer Center, Seattle, Washington, United States
7 The University of Utah, Huntsman Cancer Institute, Salt Lake City, Utah, United States
8 John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, United States
9 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
10 Atrium Health Levine Cancer Institute, Charlotte, North Carolina, United States
11 Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, United States
12 Medical University of South Carolina, Charleston, South Carolina, United States
13 City of Hope, Duarte, California, United States
14 The University of Kansas Medical Center, Kansas City, Kansas, United States
15 UT Southwestern Medical Center, Dallas, Texas, United States
16 Virginia Commonwealth University, Richmond, Virginia, United States
17 Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan, United States
18 Columbia University Irving Medical Center, New York, New York, United States
19 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
20 Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, United States
21 Stanford University School of Medicine, Stanford, California, United States
22 Mayo Clinic, Rochester, Minnesota, United States
23 H. Lee Moffitt Cancer Center, Tampa, Florida, United States
24 H. Lee Moffitt Cancer Center, Tampa, Florida, United States
25 Stanford University School of Medicine, Stanford, California, United States
26 Fred Hutchinson Cancer Center, Seattle, Washington, United States
27 H. Lee Moffitt Cancer Center, Tampa, Florida, United States
28 H. Lee Moffitt Cancer Center, Tampa, Florida, United States
29 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
30 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
31 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
32 Columbia University Irving Medical Center, New York, New York, United States
33 The University of Kansas Medical Center, Kansas City, Kansas, United States
34 Mayo Clinic, Scottsdale, Arizona, United States
35 Mayo Clinic, Jacksonville, Florida, United States
36 Medical University of South Carolina, Charleston, South Carolina, United States
37 Medical University of South Carolina, Charleston, South Carolina, United States
38 The University of Utah, Huntsman Cancer Institute, Salt Lake City, Utah, United States
39 Atrium Health Levine Cancer Institute, Charlotte, North Carolina, United States
40 Stanford University School of Medicine, Stanford, California, United States
41 The University of Utah, Huntsman Cancer Institute, Salt Lake City, Utah, United States
42 Fred Hutchinson Cancer Center, Seattle, Washington, United States
43 Fred Hutchinson Cancer Center, Seattle, Washington, United States
44 Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, United States
45 Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, United States
46 Atrium Health Levine Cancer Institute, Charlotte, North Carolina, United States
47 UT Southwestern Medical Center, Dallas, Texas, United States
48 Mayo Clinic, Rochester, Minnesota, United States
49 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
50 H. Lee Moffitt Cancer Center, Tampa, Florida, United States

Background

B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapies and T-cell engagers (TCEs) have demonstrated remarkable efficacy in relapsed/refractory multiple myeloma (RRMM), but prospective comparisons are lacking. We compared the efficacy, outcomes and safety of BCMA-directed CAR-T and TCEs in a multicenter real-world cohort of BCMA-naïve patients.

Methods

We retrospectively analyzed BCMA-naïve RRMM patients treated with cilta-cel, ide-cel,or BCMA TCEs across 18 US MM Immunotherapy Consortium centers between October 2021 and March 2025. Patients receiving <4 prior lines of therapy (LoT) were excluded. To account for baseline differences between patients treated with TCEs and CAR-T arising from treatment availability, administration logistics, and evolving regulatory indications, inverse probability of treatment weighting (IPTW) using the average treatment effect on the treated (ATT) was performed to compare cilta-cel and ide-cel with TCEs. Covariates included age, sex, race and ethnicity, Eastern Cooperative Oncology Group performance status (ECOG PS), extramedullary disease, penta-refractoriness, time from MM diagnosis to therapy initiation, and high-risk cytogenetics [using both adapted Consensus IMS/IWMG criteria and an older definition: del(17p), t(4;14), t(14;16)]. Additional sensitivity analyses included an intention-to-treat (ITT) analysis including leukapheresed but not infused patients within the CAR-T cohort. Primary outcomes included progression-free survival (PFS), overall survival (OS), response, and treatment-related toxicities.

Results

Overall, 1,374 patients met the inclusion criteria (cilta-cel, n=585; ide-cel, n=506; BCMA TCEs, n=282). Median follow-up was 17.3 months for patients treated with ide-cel, 11.1 months for cilta-cel and 7.9 months for BCMA TCEs. Patients treated with BCMA TCEs were older (median 72 years vs. 65 years for cilta-cel and 67 years for ide-cel, p<0.01). Patients treated with BCMA TCEs had worse ECOG PS [ECOG PS≥2: 36%, compared to cilta-cel (14%) and ide-cel (16%)]. Median prior LoT were 5 in all three cohorts (p<0.05), and a higher proportion of patients within the BCMA TCE cohort were penta-refractory (42% vs. 27% for cilta-cel and 32% for ide-cel). The 12-month unadjusted PFS rates were 47.0% for TCEs, 73.1% for cilta-cel and 49% for ide-cel.

Using IPTW, cilta-cel demonstrated improved PFS [hazard ratio (HR) 0.41, 95% CI 0.31–0.55; p<0.001) and OS (HR 0.36, 95% CI 0.25–0.52; p<0.001) compared with BCMA TCEs. Findings were consistent across multiple sensitivity analyses, including the ITT analysis [PFS HR 0.40 (95% CI: 0.30-0.53); OS HR 0.41 (95% CI: 0.29-0.59); both p<0.001] as well as including ferritin (with imputation) as an IPTW variable (PFS HR 0.49; OS HR 0.42, p<0.001). Cilta-cel demonstrated higher overall response rate (ORR) [odds ratio (OR) 4.54; 95% CI: 2.7-7.8; p<0.001), and complete response [(CR); OR 2.7; 95% CI: 1.8-4.1, p<0.001]. Compared to TCEs, cilta-cel was associated with higher rates of grade ≥2 cytokine release syndrome (CRS) (OR 1.7, 95% CI:1.0-2.9; p=0.05), numerically higher grade ≥3 Immune effector cell-associated neurotoxicity syndrome (ICANS) (OR 2.7, 95% CI: 0.9-7.8; p=0.08), but lower odds of severe infection (OR 0.49, p=0.003). Non-relapse mortality (NRM) was comparable [HR 0.80; p=0.47].

Patients treated with ide-cel demonstrated comparable PFS (HR 0.95, 95% CI 0.74–1.23; P=0.72) with BCMA TCEs, but improved OS (HR 0.61, 95% CI 0.45–0.83; P=0.002). Consistent results were observed on the ITT analysis [PFS HR 0.90 (95% CI: 0.69-1.16); OS HR 0.68 (95% CI: 0.50-0.92), p=0.01], as well as including ferritin (with imputation) as an IPTW variable [PFS HR 1.01; OS HR 0.63 (95% CI: 0.47-0.86), p=0.003]. Compared to TCEs, ide-cel demonstrated higher ORR (OR 1.64, P=0.03) and CR rates (OR 1.37, p=0.1) but lower day-90 ORR (OR 0.40, p<0.001). Compared with TCEs, ide-cel was associated with significantly increased grade ≥2 CRS (OR 1.68, p=0.03),  numerically higher rates for grade ≥3 ICANS (OR 2.06, p=0.2), whereas infection rates were numerically lower (OR 0.78; p=0.18).  NRM was lower with ide-cel [HR 0.37; p<0.001].

Conclusions

In this large multicenter real-world study of BCMA-naïve RRMM treated in the fourth line or later, cilta-cel demonstrated deeper responses and superior PFS and OS versus BCMA-directed TCEs after balancing key pretreatment characteristics, whereas ide-cel showed similar PFS but improved OS.

Saurabh Zanwar, MBBS, MD: International Waldenstrom Macroglobulinemia Foundation - Research Funding; International Myeloma Society - Research Funding